THE IMPACT OF METFORMIN USE ON RISK, PROGRESSION, AND SEVERITY OF DEMENTIA: A SYSTEMATIC REVIEW
Main Article Content
Keywords
Metformin, Dementia, Neuroprotection, Cognitive Function, Systematic Review
Abstract
This study aimed to investigate the impact of metformin use on the risk, progression, and severity of dementia, considering its potential neuroprotective effects. Through a comprehensive literature review and analysis of epidemiological studies, clinical trials, and comparative research, we synthesized evidence to evaluate the relationship between metformin therapy and dementia outcomes. Our findings revealed conflicting perspectives, with some studies suggesting a potential protective effect of metformin in reducing dementia risk, while others indicated mixed results regarding its influence on cognitive function and disease progression in diagnosed patients. Despite these discrepancies, our analysis underscores the importance of personalized approaches to metformin therapy and the need for further research, particularly large-scale, long-term randomized controlled trials, to clarify its therapeutic potential and optimize clinical practice in the context of dementia management.
References
2. Avan, A., & Hachinski, V. (2023). Global, regional, and national trends of dementia incidence and risk factors, 1990–2019: a Global Burden of Disease study. Alzheimer's & Dementia, 19(4), 1281-1291.
3. Barone, E., Di Domenico, F., Perluigi, M., & Butterfield, D. A. (2021). The interplay among oxidative stress, brain insulin resistance and AMPK dysfunction contribute to neurodegeneration in type 2 diabetes and Alzheimer disease. Free Radical Biology and Medicine, 176, 16-33.
4. Cui, W., Lv, C., Geng, P., Fu, M., Zhou, W., Xiong, M., & Li, T. (2024). Novel targets and therapies of metformin in dementia: old drug, new insights. Frontiers in Pharmacology, 15, 1415740.
5. Foretz, M., Guigas, B., & Viollet, B. (2019). Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus. Nature Reviews Endocrinology, 15(10), 569-589.
6. Koenig, A. M., Mechanic-Hamilton, D., Xie, S. X., Combs, M. F., Cappola, A. R., Xie, L., Detre, J. A., Wolk, D. A., & Arnold, S. E. (2017). Effects of the insulin sensitizer metformin in Alzheimer disease: pilot data from a randomized placebo-controlled crossover study. Alzheimer Disease & Associated Disorders, 31(2), 107-113.
7. Michailidis, M., Moraitou, D., Tata, D. A., Kalinderi, K., Papamitsou, T., & Papaliagkas, V. (2022). Alzheimer’s disease as type 3 diabetes: common pathophysiological mechanisms between Alzheimer’s disease and type 2 diabetes. International journal of molecular sciences, 23(5), 2687.
8. Sanati, M., Aminyavari, S., Afshari, A. R., & Sahebkar, A. (2022). Mechanistic insight into the role of metformin in Alzheimer's disease. Life Sciences, 291, 120299.
9. Sood, A., Capuano, A. W., Wilson, R. S., Barnes, L. L., Kapasi, A., Bennett, D. A., & Arvanitakis, Z. (2024). Metformin, age-related cognitive decline, and brain pathology. Neurobiology of Aging, 133, 99-106.
10. Thorpe, C. T., Gellad, W. F., Good, C. B., Zhang, S., Zhao, X., Mor, M., & Fine, M. J. (2015). Tight glycemic control and use of hypoglycemic medications in older veterans with type 2 diabetes and comorbid dementia. Diabetes care, 38(4), 588-595.
11. Wiese, L. A. K., Gibson, A., Guest, M. A., Nelson, A. R., Weaver, R., Gupta, A., Carmichael, O., Lewis, J. P., Lindauer, A., & Loi, S. (2023). Global rural health disparities in Alzheimer's disease and related dementias: State of the science. Alzheimer's & Dementia, 19(9), 4204-4225.
12. Wu, C.-Y., Shapiro, L., Ouk, M., MacIntosh, B. J., Black, S. E., Shah, B. R., & Swardfager, W. (2022). Glucose-lowering drugs, cognition, and dementia: the clinical evidence. Neuroscience & Biobehavioral Reviews, 137, 104654.
13. Xu, D., Affandi, J., Yap, T., & Reid, C. (2020). Metformin use beyond diabetes: reducing cardiovascular events in the healthy elderly. Journal of Gerontology & Geriatric Medicine, 6(058).
14. Xue, Y., & Xie, X. (2023). The association between metformin use and risk of developing severe dementia among ad patients with type 2 diabetes. Biomedicines, 11(11), 2935.
15. Koo, B. K., Kim, L. K., Lee, J. Y., & Moon, M. K. (2019). Taking metformin and cognitive function change in older patients with diabetes. Geriatrics & Gerontology International, 19(8), 755-761. https://doi.org/10.1111/ggi.13692
16. Liao, W., Xu, J., Li, B., Ruan, Y., Li, T., & Liu, J. (2022). Deciphering the roles of metformin in Alzheimer's disease: A snapshot. Frontiers in Pharmacology, 12, 728315. https://doi.org/10.3389/fphar.2021.728315
17. Imfeld, P., Bodmer, M., Jick, S. S., & Meier, C. R. (2012). Metformin, other antidiabetic drugs, and risk of Alzheimer's disease: A population-based case-control study. Journal of the American Geriatrics Society, 60(5), 916-921. https://doi.org/10.1111/j.1532-5415.2012.03916.x
18. Rotermund, C., Machetanz, G., & Fitzgerald, J. C. (2018). The therapeutic potential of metformin in neurodegenerative diseases. Frontiers in Endocrinology, 9, 400. https://doi.org/10.3389/fendo.2018.00400
19. Ji, S., Zhao, X., Zhu, R., Dong, Y., Huang, L., & Zhang, T. (2022). Metformin and the risk of dementia based on an analysis of 396,332 participants. Therapeutic Advances in Chronic Disease, 13, 20406223221109454. https://doi.org/10.1177/20406223221109454
20. Top, W. M. C., Kooy, A., & Stehouwer, C. D. A. (2022). Metformin: A narrative review of its potential benefits for cardiovascular disease, cancer, and dementia. Pharmaceuticals (Basel), 15(3), 312. https://doi.org/10.3390/ph15030312
21. Xue, Y., & Xie, X. (2023). The association between metformin use and risk of developing severe dementia among AD patients with type 2 diabetes. Biomedicines, 11(11), 2935. https://doi.org/10.3390/biomedicines11112935
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Lakachew Bekele
ECFMG Certified Medical Doctor, Department of Medicine, Holy Cross Hospital, Silver Spring, Maryland, USA,
Sundas Kanwal
Mohi-ud-Din Islamic Medical College, Mirpur, AJK,
Rabia Taj
Department of Zoology, Shaheed Benazir Bhutto Women University, Peshawar,
Raana Mahmood
Associate Professor, Department of Pharmacology, Karachi Medical & Dental College, KMU (Karachi Metropolitan University),
Paula Jativa
General Practitioner, Department of Endocrinology, Pontificia Universidad Católica del Ecuador,
Nicole Yañez Villacres
General Practitioner, Department of Nephrology, Pontificia Universidad Católica del Ecuador
Aleena Shahzad
4th Year MBBS Student, Rawalpindi Medical University,